pirfenidone has been researched along with Esophageal Stenosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujiwara, Y; Fukunaga, S; Higashimori, A; Hirano, S; Hosomi, S; Kamata, N; Nadatani, Y; Nagami, Y; Ominami, M; Otani, K; Taira, K; Tanaka, F; Tanigawa, T; Watanabe, T | 1 |
| Aguirre-Jauregui, O; Armendáriz-Borunda, J; Lucano-Landeros, MS; Orozco-Perez, J; Salazar-Montes, AM; Sobrevilla-Navarro, AA | 1 |
2 other study(ies) available for pirfenidone and Esophageal Stenosis
| Article | Year |
|---|---|
Pirfenidone prevents esophageal stricture by inhibiting nucleotide binding oligomerization domain like receptor protein 3 inflammasome activation.
Topics: Animals; Carrier Proteins; Caspase 1; Constriction, Pathologic; Esophageal Stenosis; Fibrosis; Humans; Inflammasomes; Interleukin-1beta; NLR Family, Pyrin Domain-Containing 3 Protein; Nucleotides; Pyridones; Rats; Ulcer | 2022 |
Pirfenidone prevents rat esophageal stricture formation.
Topics: Animals; Antineoplastic Agents; Connective Tissue Growth Factor; Drug Evaluation, Preclinical; Esophageal Stenosis; Esophagitis; Fibrosis; Gene Expression; Male; Plasminogen Activator Inhibitor 1; Pyridones; Rats, Wistar; Sodium Hydroxide; Transforming Growth Factor beta1; Wound Healing | 2015 |